Copper Cu 64-DOTA-Trastuzumab PET in Predicting Response to Treatment With Ado-Trastuzumab Emtansine in Patients With Metastatic HER2 Positive Breast Cancer

Clinical trial NCT02226276 · ACTIVE_NOT_RECRUITING

Trial details

NCT number: NCT02226276
Sponsor: City of Hope Medical Center
Status: ACTIVE_NOT_RECRUITING
Phase: Not Applicable
Study type: INTERVENTIONAL

Bone Metastases HER2-positive Breast Cancer Liver Metastases Lung Metastases Recurrent Breast Cancer Soft Tissue Metastases Stage IV Breast Cancer

Start date: 2015-01-07
Primary completion: 2021-12-07
Enrollment: 10

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.